RecruitingNot ApplicableNCT05718245

HEPA, PM2.5, and Cardiometabolic Health

Using Indoor Air Filtration to Reduce PM2.5 Cardiometabolic Effects in At-risk Individuals

Sponsor

University of Southern California

Enrollment

52 participants

Start Date

Mar 15, 2023

Study Type

INTERVENTIONAL

Conditions

Cardiometabolic health Air Pollution

Summary

The goal of this randomized, double-blind, crossover trial is to test the hypothesis that a longer-term indoor HEPA filtration intervention can improve cardiometabolic profiles by reducing indoor PM2.5 exposures in at-risk individuals.

Eligibility

Min Age: 65 YearsMax Age: 84 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called HEPA filter and a medical device called Sham filter for people with air pollution and cardiometabolic health. The study is currently recruiting participants at 1 location. People eligible for this study include aged 65 Years to 84 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.